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The inhibitory effect of coagulation factor XIII (FXIII) on fibrinolysis has been studied for at least 50 years. Our insight into
the underlying mechanisms has improved considerably, aided in particular by the discovery that activated FXIII cross-links 𝛼2-
antiplasmin (𝛼2AP) to fibrin. In this review, the most important effects of different cross-linking reactions on fibrinolysis are
summarized. A distinction ismade between fibrin-fibrin cross-links studied in purified systems and fibrin-𝛼2AP cross-links studied
in plasma or whole blood systems.While the formation of 𝛾 chain dimers in fibrin does not affect clot lysis, the formation of 𝛼 chain
polymers has a weak inhibitory effect. Only strong cross-linking of fibrin, associated with high molecular weight 𝛼 chain polymers
and/or 𝛾 chain multimers, results in a moderate inhibition fibrinolysis. The formation of fibrin-𝛼2AP cross-links has only a weak
effect on clot lysis, but this effect becomes strong when clot retraction occurs. Under these conditions, FXIII prevents 𝛼2AP being
expelled from the clot and makes the clot relatively resistant to degradation by plasmin.
1. Introduction
Coagulation factor XIII (FXIII) is activated by thrombin into
activated FXIII (FXIIIa). FXIIIa is a transglutaminase that
catalyzes the formation of isopeptide bonds between the free
amine group of a lysine residue and the acyl group at the
end of the side chain of a glutamine residue [1]. FXIII was
formerly named the fibrin-stabilizing factor, as the formation
of the isopeptide bonds in fibrin results in the stabilization
of fibrin. Cross-linking makes fibrin clots insoluble in weak
acid or urea [2] and strongly modifies the physical properties
such as clot stiffness [3]. In addition, cross-linking of fibrin
makes the clot more resistant to proteolytic degradation by
the fibrinolytic system.
Inherited FXIII deficiency with undetectable FXIII activ-
ity is associated with a severe bleeding tendency. Umbilical
bleeding a few days after birth is a characteristic feature and
occurs in about 80% of the cases, while intracranial hemor-
rhage at birth constitutes a main threat to life [4]. It is not
fully establishedwhichmechanisms are primarily responsible
for the bleeding tendency. These mechanisms may involve
the lack of physical stabilization of fibrin, the enhanced
sensitivity to fibrinolysis, and/or even other mechanisms.
In this paper, we will review the effect of FXIII on
fibrinolysis, in particular on the extent of inhibition of lysis
and the biochemical mechanisms that are involved. There
has been a long-running debate on these topics with many
apparently conflicting reports.While reviewing the literature,
it is helpful to distinguish mechanisms that play a role in
purified fibrin clots and mechanisms that play a role in
plasma or whole blood clots where cross-linking of other
proteins could occur. This paper shows that most important
mechanisms are gradually being elucidated. Excellent reviews
about FXIII, including its effect on fibrinolysis, have been
published earlier [1, 5].
2. The Fibrinolytic System
The conversion of the inactive proenzyme plasminogen into
the active enzyme plasmin is the central step in the fibri-
nolytic system [6]. Plasmin degrades fibrin into soluble fibrin
degradation products. Two physiologic plasminogen activa-
tors are capable of catalyzing the conversion of plasminogen:
tissue-type and urokinase-type plasminogen activator (t-PA
and u-PA, resp.). The most important plasminogen activator
for fibrin degradation is probably t-PA, although u-PA may
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also be involved in a complementary action of t-PA and u-
PA [7]. In the absence of fibrin, t-PA is a poor plasminogen
activator. However, in the presence of fibrin, the plasminogen
activator activity of t-PA is two orders of magnitude higher as
a result of the binding of both t-PA and plasminogen to fibrin
and the formation of a cyclic ternary complex. This makes t-
PA a fibrin-specific agent.
Inhibition of the fibrinolytic system may occur at the
level of plasminogen activation, mainly by plasminogen
activator inhibitor-1 (PAI-1) [8]. The two chain forms of t-
PA and u-PA are also efficiently inhibited by plasminogen
activator inhibitor-2 (PAI-2), but the plasma levels of PAI-
2 are normally low or even undetectable (except during
pregnancy), and other intracellular functions of PAI-2 have
been postulated [9]. Inhibition of the fibrinolytic systemmay
also occur at the level of plasmin, mainly by 𝛼2-antiplasmin
(𝛼2AP) [10]. PAI-1 and PAI-2, as well as 𝛼2AP, are mem-
bers of the serine protease inhibitor (serpin) superfamily.
Fibrin degradation is additionally inhibited by thrombin-
activatable fibrinolysis inhibitor (TAFI) [11]. TAFI represents
a link between coagulation and fibrinolysis. The inhibitor is
slowly activated by thrombin, but this activity of thrombin
is three orders of magnitude higher in the presence of
thrombomodulin. The activated form (TAFIa) is a plasma
carboxypeptidase B and has a short half-life of about 10min
under physiologic conditions. The antifibrinolytic activity of
TAFIa is based on the elimination of C-terminal lysine and
arginine residues from partially degraded fibrin. This results
in a strongly reduced binding of plasminogen on partially
degraded fibrin and a concomitant reduction of the activation
of plasminogen [12].
Two types of lysis can be distinguished both in vivo and in
vitro: external and internal lysis [13]. In internal lysis, all fib-
rinolytic components are homogeneously distributed within
the clot, whereas in external lysis plasminogen activators, t-
PA or u-PA, are acting from the outside of the clot. In in
vitro experiments, internal lysis is accomplished by adding
plasminogen activator to fibrinogen, plasma, or blood before
clot formation is induced, while external lysis is obtained
by the incubation of a preformed clot in a milieu which is
enriched in a plasminogen activator.
3. Effect of Factor XIIIa on Lysis of
Purified Fibrin Clots
Cross-linkage of fibrin by FXIIIa results in a rapid formation
(within minutes under physiological conditions) of cross-
links between 𝛾 chains yielding 𝛾 chain dimers and in a slower
formation (minutes to hours) of cross-links between 𝛼 chains
yielding𝛼 chain polymers consisting of a varying number of𝛼
chains. 𝛽 chains are not involved directly in the cross-linking
of fibrin [14]. Only a small number of 𝛼 chain polymers have
been formed by the time all the 𝛾 chains have been linked,
illustrating the difference in reaction rates. A minor amount
of cross-linking also occurs between𝛼 and 𝛾 chains and, upon
prolonged incubation (hours to days), between interfibril 𝛾
chains resulting in 𝛾 chain trimers and 𝛾 chain tetramers [15].
Some early fibrinolysis studies did not find an effect of
FXIIIa on the lysis of purified fibrin clots [16, 17]. Francis
and Marder [18], however, were able to demonstrate that the
intramolecular cross-links producing 𝛼 chain polymers, in
particular the very high molecular weight 𝛼 chain polymers
obtained with elevated FXIIIa concentrations, are associated
with the inhibition of fibrinolysis. In addition, Siebenlist and
Mosesson [19] found inhibition of lysis by FXIIIa and claimed
that resistance to fibrinolysis is not induced by 𝛼 chain
polymer formation or 𝛾 chain dimer formation, but by 𝛾 chain
multimer formation. Although the latter two studies disagree
about the responsible structures, they agree that inhibition
of fibrinolysis occurs particularly after a very strong cross-
linking of fibrin. It is quite possible that the studies that
found no or only a small effect did not induce such a strong
cross-linking. Indeed, recent studies demonstrating small
inhibitory effects of fibrin cross-linking on fibrinolysis were
not performed under strong cross-linking conditions [20].
The small inhibitory effects of the latter study were also
observed with a recombinantmutant of fibrinogen (𝛾Q398N/
Q399N/K406R), which does not allow for 𝛾 chain cross-
linking, suggesting that 𝛼 chain cross-linking explained the
inhibition [21]. This is in line with the above-mentioned
conclusion from Francis and Marder [18].
4. Effect of Factor XIIIa on Lysis of
Fibrin Clots Prepared from Plasma or
Whole Blood
FXIIIa does not only catalyze intramolecular cross-links
within fibrin but also catalyze intermolecular cross-links
between fibrin and other proteins. In a recent proteomic
study, 48 proteins were found to be cross-linked to plasma
clots [22]. In particular, proteins with an inhibitory effect on
fibrinolysis are of importance for clot stability.These proteins
include 𝛼2AP, PAI-2, TAFI, and complement C3. Cross-
linking of 𝛼2AP occurs via Gln14 in 𝛼2AP and Lys303 in
the 𝛼 chain of fibrin [23]. Other minor cross-linking sites
in 𝛼2AP are Gln34, Gln431, and Gln459 [24]. Cross-linking
of PAI-2 occurs via Gln83 and Gln86 in PAI-2 and at one
of six lysine residues in the 𝛼 chain of fibrin, but not at
Lys303 [25]. Potential cross-linking sites in TAFI are Gln2,
Gln5, and Gln292 [26]. Finally, recent studies suggest that
complement C3 prolongs fibrinolysis and is cross-linked to
fibrin by FXIIIa [27]. The mechanism of the inhibition of
fibrinolysis by complement C3 has not yet been elucidated. As
described below, the cross-linking of 𝛼2AP has the strongest
effect on fibrinolysis as compared to the cross-linking of PAI-
2, TAFI, and complement C3.
5. Cross-Linking of 𝛼2-Antiplasmin to Fibrin
An important discovery for the mechanism of the inhibition
of fibrinolysis by FXIII is that FXIIIa cross-links 𝛼2AP to
fibrin when blood is clotted in the presence of calcium ions
[28]. The cross-linked 𝛼2AP is fully active and essential for
the inhibition of fibrinolysis, particularly of spontaneous
fibrinolysis by t-PA-induced plasminogen activation on the
fibrin surface [29].The cross-linking of 𝛼2AP to fibrin occurs
rapidly; maximal 𝛼2AP cross-linking is almost reached when
𝛼 chain polymerization has just started [30]. An unexplained
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phenomenon is that the cross-linking of 𝛼2AP stops at about
30% incorporation (corresponding to about one 𝛼2AP mole-
cule per 25 molecules of fibrin), whereas the cross-linking
of fibronectin to fibrin in the same experiments continues
to about 100%. Enhancing the concentrations of FXIIIa
increases the rate of 𝛼2AP cross-linking but does not change
the maximal incorporation [30]. It has been suggested that
FXIIIa not only accelerates the cross-linking of 𝛼2AP but also
accelerates the release of cross-linked𝛼2AP and that the latter
activity explains the partial incorporation [31]. However,
other mechanisms related to 𝛼2AP heterogeneity (see below)
or structural hindrance by 𝛼 chain polymerization should be
considered as well, although structural hindrance does not
appear to play a role in the cross-linking of 𝛼2AP to fibrino-
gen [32].
It is somewhat remarkable that higher levels of FXIII do
not increase the maximal level of 𝛼2AP cross-linking [30],
whereas the Leu variant of the Val34Leu polymorphism of
FXIII, which is more rapidly activated by thrombin than the
Val variant, shows a higher incorporation of 𝛼2AP than the
Val variant.This occurs in plasma samples of healthy subjects
[33] as well as in purified systems [34]. The two latter studies
utilized the same microtiter plate incorporation assay. This
suggests that the assay reflects the rate of 𝛼2AP incorporation
more than the maximal incorporation.
6. Heterogeneity of 𝛼2-Antiplasmin
In the circulation, 𝛼2AP undergoes both N-terminal and C-
terminal proteolytic modifications that significantly modify
its functional properties [10]. Approximately 35% of cir-
culating 𝛼2AP lacks the C-terminus containing the bind-
ing site for plasmin(ogen) which is crucial for the rapid
inhibitory mechanism of 𝛼2AP [35]. Although this so-
called nonplasminogen-binding form of 𝛼2AP has not yet
been purified and biochemically characterized, there is evi-
dence that 𝛼2AP with an intact C-terminus, also called
plasminogen-binding form, is selectively cross-linked to
fibrin by FXIIIa [36].
Approximately 70% of circulating 𝛼2AP is cleaved at the
N-terminus between Pro12 and Asn13 of full-length 𝛼2AP
which has Met as the N-terminus (Met-𝛼2AP) [37]. The 12-
residue shorter form has Asn as the N-terminus (Asn-𝛼2AP)
and is cross-linked to fibrin ∼13 times faster than Met-𝛼2AP,
probably because the cross-linking siteGln14 ismore exposed
inAsn-𝛼2AP than it is inMet-𝛼2AP [38]. Lysis rates of plasma
clots are slower when the plasma samples contain relatively
more Asn-𝛼2AP [38]. The enzyme that cleaves Met-𝛼2AP in
vitro is named antiplasmin-cleaving enzyme (APCE) and is
identical to the soluble form of membrane-bound fibroblast
activation protein in the circulation (cFAP) [38]. Correlation
studies of circulating cFAP levels and percentage 𝛼2AP N-
terminal cleavage in the plasma samples of patients and
healthy controls confirm that cFAP is also responsible for the
cleavage in vivo [39, 40]. The 𝛼2AP gene codes for either Arg
or Trp as the sixth amino acid. cFAP cleavesMet-𝛼2AP(Arg6)
∼8-fold faster than Met-𝛼2AP(Trp6), suggesting that this
Arg6Trp polymorphism may be functionally significant
[41].
If we assume that the N-terminal and C-terminal pro-
teolytic modifications of 𝛼2AP occur independently of each
other, we can calculate that 65% × 70% = 45.5% of the 𝛼2AP
in plasma has a form (Asn-plasminogen-binding 𝛼2AP) that
is rapidly incorporated in fibrin by FXIIIa. This may partially
explain why the maximal incorporation of 𝛼2AP is only
∼30%.
7. Relative Contributions of Fibrin-Fibrin
Cross-Links and Fibrin-𝛼2-Antiplasmin
Cross-Links to Inhibition of Lysis
During blood clotting, FXIIIa introduces cross-links within
fibrin as well as between fibrin and 𝛼2AP. The relative
contributions of the two types of cross-links in the inhibition
of fibrinolysis by FXIII have been thoroughly investigated.
Jansen et al. [42] studied the lysis rate of fresh whole blood
clots containing t-PA that was added before clotting in
vitro. They reported that fibrin-𝛼2AP cross-linking explains
the FXIIIa-induced resistance of blood clots to fibrinolysis,
whereas fibrin-fibrin cross-linking has only a small, if any,
influence. This was later confirmed by Fraser et al. [43], who
showed that the antifibrinolytic function of FXIII in plasma
clots prepared in a Chandler loop and incubated in a buffer
containing t-PA is independent of fibrin-fibrin cross-linking
and is expressed exclusively through 𝛼2AP. Reed and Houng
[44] studied t-PA-induced fibrinolysis in anesthetized ferrets
with pulmonary emboli and found, in contrast to the previous
investigators, that both fibrin-fibrin and fibrin-𝛼2AP cross-
linking caused resistance to lysis.
Significant inhibition of fibrinolysis by fibrin-fibrin cross-
links requires strong cross-linking conditions, resulting in
very high molecular weight 𝛼 chain polymers and/or 𝛾
chain trimers and tetramers, whereas significant inhibition
of fibrinolysis by fibrin-𝛼2AP cross-links occurs immediately
after clotting, as these links are formed rapidly. Therefore,
it can be anticipated that the relative contribution of fibrin-
fibrin cross-links to the total inhibition of fibrinolysis by
FXIII depends on the extent of cross-linking and increases,
for instance, with the age of a thrombus.
8. Effect of Clot Compaction and Clot
Retraction on Lysis
The inhibition of clot lysis by FXIII is determined not only
by the degree of cross-linking but also by the design of the
lysis experiments. This was already concluded in 1979 in a
paper about the existing controversy concerning the question
of whether or not FXIII cross-linking affects fibrinolytic rates
[45]. In this connection, Mutch et al. [46] published an
interesting observation that model thrombi formed under
flow in a Chandler loop and subsequently incubated in a
buffer containing t-PA reveal a significant effect of FXIII on
fibrinolysis. This effect is also revealed by thrombi prepared
from platelet-free plasma. It is suggested that flow is required
during clot formation.
We recently studied the effect of clot retraction on the
antifibrinolytic effect of FXIII [47], stimulated by preliminary
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Figure 1: Activated factor XIII (FXIIIa) partially prevents 𝛼2-
antiplasmin (𝛼2AP) from being expelled from a plasma clot during
compaction and thereby strongly inhibits fibrinolysis. Taken from
Rijken et al. [47].
data from Sakata and Aoki pointing to the potential impor-
tance of clot retraction [29]. Our studies started with platelet-
poor and t-PA-containing plasma clots with and without
physical compaction by centrifugation, as amodel of platelet-
mediated clot retraction. Without compaction, FXIII slightly
inhibited clot lysis (1.6-fold). With compaction, however,
FXIII revealed a strong inhibition of clot lysis (7.7-fold).
Because FXIII did not show inhibition with either com-
pacted or noncompacted clots prepared from 𝛼2AP-deficient
plasma, the inhibition was completely ascribed to the cross-
linking of 𝛼2AP, in agreement with previous studies [42, 43].
Under these conditions, the fibrin-fibrin cross-links were
apparently too limited to play a significant role. The same
held true for potential cross-links between fibrin and other
proteins such as TAFI and PAI-2. Experiments with platelet-
rich plasma clots, with and without platelet-mediated clot
retraction, showed similar results as platelet-poor plasma
clots with and without compaction. The slight inhibition by
FXIIIa of the lysis of noncompacted or nonretracted plasma
clots implied that cross-linked 𝛼2AP is a somewhat better
inhibitor of plasmin that is generated on the fibrin surface
than non-cross-linked 𝛼2AP. However, this type of inhibition
in assays without compaction or retraction is small and
probably not easily detectable since various studies in the lit-
erature report no inhibition (e.g., [45]). The extra and strong
inhibition of the lysis of compacted or retracted plasma clots
is easily explained, since FXIIIa partially prevents 𝛼2AP from
being expelled from the clot during compaction or retraction.
This mechanism is illustrated in Figure 1.
The requirement of clot compaction for the full expres-
sion of the antifibrinolytic effect of FXIII in clot lysis assays
explains the old controversy between Gaffney and Whitaker
[48] and Rampling and Flexman [45].The first authors found
a strong inhibitory effect on lysis of plasma clots harvested
by winding the clot onto a glass rod (thus with compaction),
whereas the latter authors found no inhibitory effect using
undisturbed plasma clots (thus without compaction). The
requirement of clot compaction also explains why the lysis of
Chandler loop thrombi is sensitive to FXIII [46], as Chandler
loop thrombi are always compacted. Therefore, compaction
and not the formation under flow is the essential feature a
clot must show in order to reveal FXIII-dependent clot resist-
ance.
9. (Patho)physiologic Aspects
What is the (patho)physiologic meaning of the mechanism
illustrated in Figure 1? It is not easy to answer this question,
because our knowledge of platelet-mediated clot retraction
is limited. We do not know when, where, and how fast
clot retraction occurs in the body. However, it is clear from
Figure 1 that in vivo retracted clots are fairly resistant to
fibrinolysis owing to the cross-linking of 𝛼2AP by FXIIIa.
Without FXIIIa, 𝛼2AP would be largely expelled from the
clot during retraction. It is assumed that platelet-mediated
clot retraction can occur in the absence of FXIIIa activity.
This is still a matter of debate [49], but in our hands platelet-
rich clots do retract in the presence of FXIIIa inhibitor
[47]. Full absence of FXIII in patients is rare, but low levels
do occur more frequently, for instance, in acquired FXIII
deficiency. Studies in purified systems [50] and in platelet-
poor plasma [46] indicate that plasma FXIII levels of 50% of
normal are required for the optimal inhibition of fibrinolysis.
FXIII levels below 50% are associated with a smaller 𝛼2AP
incorporation and enhanced clot lysis. Platelets and platelet
FXIII could contribute to the cross-linking of 𝛼2AP to fibrin
[51–53]. Hemostasis in FXIII-deficient patients is already
normalized at therapeutic FXIII plasma levels of 3–5% [4].
This suggests that the severe bleeding problems of FXIII-
deficient patients are not primarily caused by enhanced clot
lysis, but by impaired (physical) stability of the clots due to
insufficient formation of 𝛾 chain dimers and possibly 𝛼 chain
polymers. Enhanced fibrinolysis could contribute, however,
to the severity of the bleeding tendency, as recently observed
in a subpopulation of patients with von Willebrand disease
[54].
While enhanced fibrinolysis may be associated with
bleeding, impaired fibrinolysis could result in a thrombotic
tendency. Although the cross-linking of 𝛼2AP to fibrin seems
already to be maximal at a plasma FXIII level of 50%, the
incorporation of 𝛼2AP is only partial (about 30%) and one
could imagine that the incorporation may increase or may
become faster in certain physiologic or pathophysiological
conditions. One example is the earlier-mentioned increased
rate of𝛼2AP incorporation by the Leu variant of theVal34Leu
polymorphism of FXIII [33, 34]. Similar increases might be
caused by variations in 𝛼2AP (for instance, in the N-terminal
or C-terminal heterogeneity) or in fibrinogen.
10. Conclusions
The inhibitory effects of FXIII-mediated cross-links on fib-
rinolysis are summarized in Table 1. Fibrin-fibrin cross-links
are responsible for weak effects, although very strong cross-
linking conditions in vitro result in a moderate inhibition
of fibrinolysis. It is not yet clear to what extent these strong
cross-linking conditions occur in vivo. Fibrin-𝛼2AP cross-
links are also responsible for only weak effects, but these
cross-links result in strong inhibition of clot lysis when clot
retraction occurs. We assume that blood clotting in vivo is
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Table 1: Summary of inhibitory effects of FXIII-mediated cross-
links on fibrinolysis.
Type of cross-links Inhibitory effect
Fibrin-fibrin cross-links
(i) 𝛾 chain dimers None
(ii) 𝛼 chain polymers Weak
(iii) High molecular weight 𝛼 chain
polymers and/or 𝛾 chain multimers Moderate
Fibrin-𝛼2-antiplasmin cross-links
(i) In nonretracted fibrin clots Weak
(ii) In retracted fibrin clots Strong
often followed by platelet-mediated clot retraction, suggest-
ing that this inhibition observed in vitro is representative of
the in vivo situation.
The effects summarized in Table 1 are to a great extent
based on internal lysis experiments. In external lysis, fib-
rinolytic components are transported from the outside to
the inside of the clot by diffusion and, in particular in vivo,
by flow. This transport may be affected by cross-linking.
Although fibrin cross-linking has only minor effects on
global network structure, it has a strong effect on individual
fibers since they becomemore compact by cross-linking [55].
This will reduce the transport of, for instance, plasminogen
activators through the fibers and reduce external clot lysis.
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